Zymeworks (ZYME) Competitors

Zymeworks (NYSE:ZYME) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.

Do analysts rate ZYME or BHVN?

Zymeworks presently has a consensus target price of $19.00, suggesting a potential upside of 23.46%. Biohaven has a consensus target price of $63.42, suggesting a potential upside of 42.86%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Biohaven	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07

Does the media favor ZYME or BHVN?

In the previous week, Biohaven had 8 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Biohaven and 9 mentions for Zymeworks. Biohaven's average media sentiment score of 0.21 beat Zymeworks' score of 0.21 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings & valuation, ZYME or BHVN?

Zymeworks has higher earnings, but lower revenue than Biohaven. Zymeworks is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$76.01M	13.95	-$118.67M	-$1.50	-10.26
Biohaven	$462.51M	9.71	-$408.17M	-$9.35	-4.75

Is ZYME or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Biohaven	N/A	-225.12%	-158.89%

Which has more volatility & risk, ZYME or BHVN?

Zymeworks has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Does the MarketBeat Community believe in ZYME or BHVN?

Biohaven received 105 more outperform votes than Zymeworks when rated by MarketBeat users. However, 67.99% of users gave Zymeworks an outperform vote while only 66.89% of users gave Biohaven an outperform vote.

Company	Underperform	Outperform
Zymeworks	Outperform Votes 291 67.99%	Underperform Votes 137 32.01%
Biohaven	Outperform Votes 396 66.89%	Underperform Votes 196 33.11%

Do institutionals & insiders have more ownership in ZYME or BHVN?

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Biohaven beats Zymeworks on 11 of the 18 factors compared between the two stocks.